Exploring Precise Medication Strategies for OSCC Based on Single-Cell Transcriptome Analysis from a Dynamic Perspective DOI Open Access
Qingkang Meng, Feng Wu, Guoqi Li

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(19), P. 4801 - 4801

Published: Sept. 30, 2022

At present, most patients with oral squamous cell carcinoma (OSCC) are in the middle or advanced stages at time of diagnosis. Advanced OSCC have a poor prognosis after traditional therapy, and complex heterogeneity has been proven to be one main reasons. Single-cell sequencing technology provides powerful tool for dissecting cancer. However, current studies single-cell level static, while development cancer is dynamic process. Thus, understanding from perspective formulating corresponding therapeutic measures achieving precise treatment highly necessary, this also study directions field oncology. In study, we combined static analysis methods based on RNA-Seq data comprehensively dissect evolutionary process OSCC. Subsequently, clinical practice, revealed association between patients. More importantly, pioneered concept pseudo-time score patients, quantified levels evaluate relationship survival status same stage, finding that it closely related prognostic status. The could not only reflect tumor but used as an indicator effects drugs so medication strategy can adjusted time. Finally, identified candidate proposed precision strategies control condition two respects: blocking.

Language: Английский

Mocetinostat as a Novel Selective Histone Deacetylase Inhibitor in the Promotion of Apoptosis in glioblastoma Cell Line C6 and T98G DOI Creative Commons
Firas Khathayer,

Mohammad Hussein Mikael

Biomedical and Biotechnology Research Journal (BBRJ), Journal Year: 2024, Volume and Issue: 8(3), P. 328 - 339

Published: July 1, 2024

Abstract Background: Histone deacetylase (HDAC) enzymes play a crucial role in regulating gene expression and epigenetic alterations cancer cells. Mocetinostat (MGCD0103) is novel, isotype-selective HDAC inhibitor that targets Class I (HDAC1, 2, 3, 8) IV (HDAC11) enzymes. It has been approved for the use phase II trials Hodgkin’s lymphoma. Methods: In this study, glioblastoma cell (GBM) lines T98G C6 were treated with different concentrations of MGCD0103 (0.0, 0.5, 1.0, 1.5, 2.0, 2.5 μM). Western blot analysis was used to evaluate protein flow cytometry employed assess apoptosis. Results: The results demonstrated exerts multiple anti-cancer activities GBMs. modulated key signaling pathways, including inhibition Phosphatidylinositol 3- kinase (PI3K)/protein B mechanism pathway suppression HDAC1 enzyme activity. High doses significantly induced apoptosis suppressed proliferation by upregulating pro-apoptotic Bcl-2-associated x downregulating anti-apoptotic proteins BH3 Interacting Domain Death Agonist B-cell leukemia/lymphoma 2 protein. addition, treatment upregulated tumor-suppressor downregulated E2F1 transcription factor. Furthermore, facilitated differentiation activating glial fibrillary acidic Glial Fibrillary (GFAP) as distinguish marker astrocytes, suppressing undifferentiation markers Inhibitor Deoxyribonucleic acid binding N-Myc proto-oncogene Conclusion: This research suggests promising drug inhibiting proliferation, invasion, migration findings also provide new insights into ability induce Overall, these indicate could be potent therapeutic agent target glioblastoma.

Language: Английский

Citations

0
Recent Update on Anti-tumor Mechanisms of Valproic Acid in Glioblastoma Multiforme DOI

Abulfazl Vatankhah,

Sepehr Hoseinzadeh Moghaddam,

Sadaf Afshari

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 263, P. 155636 - 155636

Published: Oct. 3, 2024

Language: Английский

Citations

0
Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors DOI
Asmita Dasgupta, Sanjukta Ghosh, Kastro Kalidass

et al.

Elsevier eBooks, Journal Year: 2023, Volume and Issue: unknown, P. 147 - 200

Published: Jan. 1, 2023

Language: Английский

Citations

1
Antiepileptic drug therapy in brain tumor patients: a complex relationship DOI Open Access
Jörg Dietrich

Neuro-Oncology Practice, Journal Year: 2022, Volume and Issue: 9(2), P. 83 - 84

Published: Jan. 28, 2022

Language: Английский

Citations

1
Exploring Precise Medication Strategies for OSCC Based on Single-Cell Transcriptome Analysis from a Dynamic Perspective DOI Open Access
Qingkang Meng, Feng Wu, Guoqi Li

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(19), P. 4801 - 4801

Published: Sept. 30, 2022

At present, most patients with oral squamous cell carcinoma (OSCC) are in the middle or advanced stages at time of diagnosis. Advanced OSCC have a poor prognosis after traditional therapy, and complex heterogeneity has been proven to be one main reasons. Single-cell sequencing technology provides powerful tool for dissecting cancer. However, current studies single-cell level static, while development cancer is dynamic process. Thus, understanding from perspective formulating corresponding therapeutic measures achieving precise treatment highly necessary, this also study directions field oncology. In study, we combined static analysis methods based on RNA-Seq data comprehensively dissect evolutionary process OSCC. Subsequently, clinical practice, revealed association between patients. More importantly, pioneered concept pseudo-time score patients, quantified levels evaluate relationship survival status same stage, finding that it closely related prognostic status. The could not only reflect tumor but used as an indicator effects drugs so medication strategy can adjusted time. Finally, identified candidate proposed precision strategies control condition two respects: blocking.

Language: Английский

Citations

1